Murphy & Mullick Capital Management Corp Roivant Sciences Ltd. Transaction History
Murphy & Mullick Capital Management Corp
- $103 Billion
- Q1 2025
A detailed history of Murphy & Mullick Capital Management Corp transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 100 shares of ROIV stock, worth $1,108. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$1,108
Previous $1.18 Million
14.71%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
332Shares Held
496MCall Options Held
3.67MPut Options Held
754K-
Qvt Financial LP New York, NY65.8MShares$729 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$685 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$510 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$452 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$398 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.8B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...